ArticleInternational journal of obesity (2005)2026
Weight-related changes in MRI-derived measures of body composition and liver steatosis: a large-scale analysis for obesity trial design.
Article in International journal of obesity (2005), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Update on Obesity and Its Relationship to Atherosclerotic Cardiovascular Disease and Associated Risk Factors.Journal of clinical medicine · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesAmid rising global obesity rates and advances in weight-loss therapies, monitoring body composition and ectopic fat could refine trial design. We quantified weight-related changes in body composition and liver steatosis prior to widespread adoption of incretin treatments. SUBJECTS/
methodsAdults (N = 3070) from the UK Biobank with repeat abdominal MRI scans were included. Percent weight change from baseline was categorised: stable (0 ± 2%), mild change (2-5% weight gain/loss), moderate change (5-10% weight gain/loss), or large change (10-15% weight gain/loss). INTERVENTION/
methodsMRI data were processed automatically from two visits, spaced 2.7 years apart, to derive volumetric visceral (VAT), subcutaneous adipose tissue (SAT), total skeletal muscle volume (SM, or indexed SM), muscle fat infiltration (MFI
resultsWeight gain occurred in 28% of all subjects (N = 3070, age 63 years, male 49%, 13% with obesity, 43% with overweight). Moderate or large weight gain increased LFC, VAT, SAT, MFI
conclusionsUsing MRI, relative changes in body composition and liver steatosis resulting from weight loss can inform clinical trials, including placebo arm design and power estimations. Weight changes affect body composition and liver fat and can inform obesity trial design.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.